Teva is leading the development and will handle the global commercialization of this olanzapine LAI. UZEDY  is now available in the United States through Teva, under the licensed name SteadyTeq .The collaboration between Teva and MedinCell underscores a commitment to advancing treatment options for schizophrenia, a chronic brain disorder that affects about 1  of the population worldwide. MONTPELLIER, France - Teva Pharmaceutical Industries  NYSE TEVA  Ltd. has announced the completion of patient enrollment for its Phase 3 trial of mdc-TJK, a potential new treatment for schizophrenia.
Teva is leading the development of mdc-TJK, a potential new treatment for schizophrenia, with patient enrollment for its Phase 3 trial now complete. The collaboration between Teva and MedinCell underscores a commitment to advancing treatment options for schizophrenia, which affects about 1% of the population worldwide.